Investors & Media Investors & Media

What’s new.

Analyst reports

Analyst reports.

July 11th 2025

Jefferies - Efti/Pembro Looks Good vs. Other Combos and Other Therapies in NSCLC and HNSCC; Rated BUY, PT A$2.10 (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

June 23rd 2025

Baird - Updated Phase 1 Safety/Efficacy HV Data for IMP761 (LAG-3) for Autoimmune; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

June 23rd 2025

Canaccord Genuity - IMP761 PhI shows good safety and T cell suppression; BUY, A$0.98 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor



E-MAIL UPDATES

registration.

Please fill out the registration form below to receive updates and announcements by e-mail.